Abstract: An anti-oxidation dipping treatment method for a graphite sealing element for a thermal power generation unit, and an anti-oxidation production line. The anti-oxidation dipping treatment method for a graphite sealing element for a thermal power generation unit comprises the following steps: S1, placing a graphite sheet into a soaking device for soaking; S2, conveying the soaked graphite sheet into a drying and curing device for drying and curing; S3, stacking the multiple dried and cured graphite sheets together, and subjecting same to compression molding to form a layered graphite body; and S4, stamping the layered graphite body to form a finished graphite sealing element with a desired appearance.

Abstract: A metal alloy is for use at very high temperature, in particular the metal alloy can be used in a process for the manufacture of mineral wool by fiberizing a molten mineral composition. The metal alloy contains the following elements, the proportions being shown as percentage by weight of the alloy: Cr 20 to 35% Fe 10 to 25% W 2 to 10% Nb 0.5 to 2.5% Ti 0 to 1% C 0.2 to 1.2% Co less than 5% Si less than 0.9% Mn less than 0.9% the remainder consisting of nickel and unavoidable impurities.

Abstract: A Ni—Cr—Fe-based casting alloy is provided for use in manufacturing a component for contacting molten glass, such as a centrifugal spinner for forming fibers of a molten glass by a rotary fiber forming process, for example. This Ni—Cr—Fe-based casting alloy is suitable for use in manufacturing a component for contacting molten glass, and contains, in terms of mass percent, 15-30% Cr, 15-30% Fe, 2.5-5.0% Co, 3.0-6.0% W, 0.0-2.0% Ti, 0.5-2.5% Nb, 0.5-2.0% Mo, and 0.5-1.2% C, the remainder including nickel and unavoidable impurities.

Abstract: A metal alloy is for use at very high temperature, in particular the metal alloy can be used in a process for the manufacture of mineral wool by fiberizing a molten mineral composition. The metal alloy contains the following elements, the proportions being shown as percentage by weight of the alloy: Cr 20 to 35% Fe 10 to 25% W 2 to 10% Nb 0.5 to 2.5% Ti 0 to 1% C 0.2 to 1.2% Co less than 5% Si less than 0.9% Mn less than 0.9% the remainder consisting of nickel and unavoidable impurities.

Abstract: A Ni—Cr—Fe-based casting alloy is provided for use in manufacturing a component for contacting molten glass, such as a centrifugal spinner for forming fibers of a molten glass by a rotary fiber forming process, for example. This Ni—Cr—Fe-based casting alloy is suitable for use in manufacturing a component for contacting molten glass, and contains, in terms of mass percent, 15-30% Cr, 15-30% Fe, 2.5-5.0% Co, 3.0-6.0% W, 0.0-2.0% Ti, 0.5-2.5% Nb, 0.5-2.0% Mo, and 0.5-1.2% C, the remainder including nickel and unavoidable impurities.

Abstract: The present invention relates to the application of multidimensional matrix for drug design and the methodology for drug design, which for the first time introduces the concept of matrix optimization in mathematics to the design of drugs and the relevant molecules. The present invention uses multidimensional matrix to analyze the permutation and combination of factors that affect the chemical structures and properties of drugs, and classifies and compares the huge amounts of factors need to be considered in the drug discovery according to certain features, thus utilizes fewer number of variables to represent the huge number of variable factors to specifically obtain chemical structures for effective drugs and improves the physicochemical properties of the compounds.

Abstract: N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, pharmaceutically acceptable salts thereof, and/or mixtures thereof, as well as, pharmaceutical compositions thereof, methods of treatment therewith, and processes of making N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide and intermediates thereof.

Abstract: The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

Abstract: N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, pharmaceutically acceptable salts thereof, and/or mixtures thereof, as well as, pharmaceutical compositions thereof, methods of treatment therewith, and processes of making N-(2-hydroxyethyl)-N-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide and intermediates thereof.